Glyxambi (Empagliflozin)
✅ Controls blood sugar levels
✅ Reduces heart disease risk
✅ Promotes weight loss
✅ Lowers blood pressure
✅ Improves kidney function
Glyxambi contains Empagliflozin & Linagliptin
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
⚡ Quick Answer — What is Glyxambi?
Glyxambi is a fixed-dose combination tablet of empagliflozin (SGLT-2 inhibitor) și linagliptin (DPP-4 inhibitor) (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) used for type 2 diabetes. It combines two non-insulinotropic mechanisms: empagliflozin causes the kidneys to excrete glucose in urine (for glycaemic, weight, BP, heart-failure, and kidney benefits), while linagliptin raises incretin hormones to stimulate glucose-dependent insulin release. Expected HbA1c reduction: 1.0–1.3 points — more than either component alone. Expected weight loss: 2–3 kg. Very low hypoglycaemia risk on its own. Once-daily dosing, with or without food. Main side effects: genital thrush, UTI, and rare DKA (empagliflozin); rare pancreatitis or arthralgia (linagliptin). Avoid in type 1 diabetes, DKA, eGFR < 30, and severe hepatic impairment.
📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.
De ce să comanzi de la MedsBase
Medicamentele noastre generice sunt procurate de la producători certificați WHO-GMP și expediate la nivel mondial în ambalaje discrete și simple — fără denumirea medicamentului pe exteriorul coletului. Plățile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de plăți cu card reglementat — niciodată “MedsBase” sau numele vreunui medicament). Acceptăm și criptomonede și transferuri bancare SEPA. Fiecare comandă este susținută de Politica noastră de Asigurare pentru Relivrare.
What Is Glyxambi?
Glyxambi is a fixed-dose combination oral antidiabetic tablet containing two active ingredients: empagliflozin (SGLT-2 inhibitor) and linagliptin (DPP-4 inhibitor), in strengths of Empagliflozin 10 or 25 mg + Linagliptin 5 mg. Manufactured by Boehringer Ingelheim / Eli Lilly; available in packs of 30, 60, 90 or 180 tablets. It is prescribed for adults with type 2 diabetes — typically added to metformin, or initiated in patients with significant hyperglycaemia who would benefit from two non-insulinotropic mechanisms in a single tablet.
How Does Glyxambi Work?
The two components target hyperglycaemia through completely separate pathways — one insulin-independent, one incretin-based:
- Empagliflozin blocks SGLT-2 in the kidney proximal tubule, causing 70–90 g of glucose to be excreted in urine each day. This lowers blood glucose independently of insulin and also reduces weight (2–3 kg), blood pressure (3–5 mmHg), heart-failure hospitalisations (EMPEROR trials), and CKD progression (EMPA-KIDNEY).
- Linagliptin blocks the enzyme DPP-4, raising levels of the incretin hormones GLP-1 and GIP. This stimulates glucose-dependent insulin release and suppresses glucagon — only when blood glucose is elevated. Linagliptin is unique among DPP-4 inhibitors in needing no renal dose adjustment.
Because neither component directly stimulates insulin release in a glucose-independent manner, Glyxambi has a very low hypoglycaemia risk on its own. Expected HbA1c reduction: 1.0–1.3 percentage points over either component alone.
Dosage and Administration
Usual dose: one tablet once daily in the morning, with or without food. The starting strength depends on prior therapy and glycaemic target.
- Miss a dose? Take as soon as you remember if it is within 12 hours; otherwise skip.
- Renal dosing: empagliflozin is limited to eGFR > 20 for HF/CKD indications (> 30 for glycaemic control); linagliptin needs no renal dose adjustment. The combination is typically avoided if eGFR < 30.
- Sick-day rules: pause during acute illness with vomiting, diarrhoea, or reduced oral intake (risk of euglycaemic DKA and AKI). Restart when eating and drinking normally.
- Do not start within 48 hours of major surgery or IV contrast.
Efecte Secundare
Common (mostly from the empagliflozin component):
- Genital mycotic infections (thrush) — up to 10% of users
- Urinary tract infections
- Polyuria, mild dehydration, postural dizziness in the first 2 weeks
- Modest LDL-cholesterol rise
From the linagliptin component:
- Nasopharyngitis, headache, mild GI upset
Uncommon but important:
- Diabetic ketoacidosis (DKA) — rare; can occur at near-normal blood glucose (“euglycaemic DKA”). Symptoms: nausea, vomiting, abdominal pain, deep breathing. Stop the drug and seek urgent care.
- Volume depletion, AKI — higher risk on diuretics or with acute illness
- Acute pancreatitis, severe arthralgia, bullous pemphigoid — rare DPP-4 class effects
- Fournier’s gangrene — extremely rare but serious
Interacțiuni medicamentoase
- Diuretics (loop and thiazide) — additive volume loss; consider diuretic dose reduction.
- Insulin, sulfonylureas, meglitinides — additive glucose-lowering; may need dose reduction to avoid hypoglycaemia.
- Rifampicin — reduces levels of both components.
- Antihipertensive — additive BP-lowering.
Who Should Not Take Glyxambi?
- Type 1 diabetes mellitus
- Diabetic ketoacidosis — current or recent history
- Severe renal impairment (eGFR < 30)
- Severe volume depletion or hypotension
- Severe hepatic impairment
- History of pancreatitis (relative)
- Known hypersensitivity to either component
- Pregnancy and breastfeeding
Depozitare
Store Glyxambi below 30°C in a dry place. Keep out of reach of children.
Întrebări frecvente
Why combine an SGLT-2 inhibitor and a DPP-4 inhibitor in one tablet?
The two classes work by completely different mechanisms that do not overlap, so the HbA1c reduction of the combination is additive (1.0–1.3 points) rather than redundant. Both are weight-neutral to weight-favourable, and both have a very low hypoglycaemia risk, making the combination a good fit for patients who need additional glucose control without adding insulin or sulfonylurea risk.
Will Glyxambi help me lose weight?
Yes, modestly — typically 2–3 kg over 6–12 months. The weight loss comes from the empagliflozin component (urinary glucose excretion). Linagliptin is weight-neutral.
Does Glyxambi protect my heart and kidneys?
The empagliflozin component has strong evidence from EMPA-REG, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY trials for cardiovascular, heart failure, and kidney protection. Linagliptin is cardiovascular-neutral in CARMELINA. So the combination retains the empagliflozin cardio-renal benefits.
Will Glyxambi cause low blood sugar?
On its own, very rarely. Neither component stimulates insulin release in a glucose-independent manner. Hypoglycaemia becomes a concern when Glyxambi is combined with a sulfonylurea, meglitinide, or insulin.
What about thrush?
Genital thrush is the most common side effect (up to 10% of users, mostly women). It is usually mild and easily treated. Most patients do not need to stop Glyxambi.
Where can I buy Glyxambi online?
You can order Glyxambi (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.
Related Diabetes Medications
- Jardiance — Empagliflozin monotherapy
- Trajenta — Linagliptin monotherapy
- Forxiga — Dapagliflozin (SGLT-2 alternative)
- Januvia — Sitagliptin (DPP-4 alternative)
- Trajenta Duo — Linagliptin + Metformin
- Glycomet SR — Metformin sustained-release
- Browse all Diabetes Medications
Alternative conexe
Alte produse din Afecțiuni cronice pe care clienții le vizualizează de asemenea:
More options in Diabetes
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Concentrație | 25mg/5mg |
|---|---|
| Cantitate | 10 Tablet/s, 30 Tablet/s, 60 Tablet/s, 90 Tablet/s |
Glyxambi (Empagliflozin)
Întrebări și răspunsuri
Glyxambi (Empagliflozin)
Produse similare
Recenzii
Nu există recenzii încă